Medicare GLP‑1 Discount Shows Eligibility Limits as Use of Weight‑Loss Drugs Soars
Medicare has started an 18‑month demonstration that offers Wegovy, Zepbound KwikPen and Foundayo for $50 a month, but only to enrollees with Part D who meet a BMI of 35 or higher, or a BMI of 27‑34 with certain conditions such as prediabetes or cardiovascular disease. Patients whose prescription is for a non‑weight‑loss indication, such as severe obstructive sleep apnea, must use regular Part D coverage and face much higher copays.
At the same time, pharmacists report that GLP‑1 drugs are being prescribed to people without obesity who seek rapid cosmetic weight loss, raising safety concerns. National data show a modest dip in obesity prevalence from 2021 to 2023, coinciding with a more than quadruple increase in GLP‑1 prescriptions since 2021, while bariatric surgery volumes fell 34.1% between 2022 and 2024.
Why it matters
The program’s eligibility rules and the growing off‑label use of GLP‑1 drugs affect both patients’ out‑of‑pocket costs and broader public‑health outcomes.
How the sides frame it
LOW AGREEMENTCenter coverage presents the GLP-1 surge as a mixed picture, detailing policy eligibility limits, potential health benefits and socioeconomic inequities, while right-leaning coverage stresses safety alarms, healthcare disruptions and changes to consumer habits.
CENTER
Center coverage presents the GLP-1 surge as a mixed picture, noting potential health benefits while emphasizing eligibility constraints and socioeconomic disparities.
RIGHT
Right coverage stresses the disruptive and risky side of GLP-1 popularity, highlighting safety concerns, healthcare system strain, and shifts in consumer behavior.
The right emphasises
- pharmacists sound alarm over popular drugs used for weight loss
- NYC sees sharp increase in needle-stick injuries, thanks to rising popularity of GLP-1 drugs
- GLP-1 boom could reshape restaurant bars as diners cut back on alcohol
How this story developed
- Aug 20 GLP-1 weight-loss drugs are disrupting U.S. healthcare economics
- Aug 25 Medicare launched an 18‑month GLP‑1 discount demonstration with specific BMI and condition criteria, leaving some patients ineligible.
